Abiraterone and Increased Survival in Metastatic Prostate Cancer
Abiraterone acetate (Zytiga™) is a medicine licensed to treat advanced prostate cancer that has spread to other areas of the body (metastasized). It is used in combination with prednisone and works by lowering testosterone in the prostate cancer cells and the adrenal gland.
Clinical studies have shown an increased survival rate in men with metastatic prostate cancer who took abiraterone. In these studies, abiraterone was shown to extend life by up to four months in men with late-stage prostate cancer who were previously treated with docetaxel (Taxotere®), a chemotherapy treatment.
(For more information, click Abiraterone. This Web resource offers more information on how abiraterone works to increase survival in men with metastatic prostate cancer. It also covers dosing guidelines, possible side effects, and general safety precautions.)